Differently with the mice fed an HFD, the mice fed a NCD did not show any significant apparent abnormalities in organs and tissues, including visceral WAT, scWAT and the liver (Figure S10), suggesting safety profiles and the specificity of targeting CXXC5‐Dvl PPI for the development of drugs for metabolic diseases. This evidence concerns the gene CXXC5 and metabolic disease.